不同剂量干扰素-α治疗HBeAg阳性慢性乙型肝炎患儿的疗效分析

Analysis on clinical effects of different doses of interferon-αin treating children with HBeAg-positive chronic hepatitis B

目的研究不同剂量的普通干扰素-α、治疗乙型肝炎病毒e抗原(HBeAg)阳性慢性乙型肝炎(乙肝)患儿的临床效果。方法选取80例HBeAg阳性的慢性乙肝患儿,随机均分为标准剂量组(普通干扰素-α5mU/m2体表面积,3次/周,治疗6个月)和高剂量组(普通干扰素-α以10mU/m2体表面积,3次/周,治疗6个月)。结果高剂量组的HBV DNA阴转率明显高于标准剂量组,两组比较差异有统计学意义(P<0.05)。丙氨酸氨基转移酶复常率、乙肝病毒表面抗原血清转换率、HBeAg血清转换率和不良反应发生率两组比较差异均无统计学意义(P>0.05)。结论两种剂量的普通干扰素-α治疗HBeAg阳性慢性乙肝患儿均安全、有效,高剂量较标准剂量能更快地抑制HBV DNA的复制。

Objective To investigate the clinical effects of different doses of common interferon-α in the treat- ment of children with HBeAg-positive chronic hepatitis B. Methods 80 children patients with HBeAg-positive chron- ic hepatitis B in our hospital were selected and randomly divided into the standard-dose group（common interferon-a 5MU/m2 body surface area,3 times per week for 6 months） and the high-dose group（common interferon-a 10MU/m2 body surface area,3 times per week for 6 months）. Results The HBV DNA negative-converting rate of the high-dose group was significantly higher than that of standard-dose group（P〈0.05）. There was no statistical difference in the ALT normalization rate, HBeAg seroconversion rate, HBsAg seroconversion rate and occurrence rate of adverse reac- tions between the two groups（P〈0.05）. Conclusion The two doses of common interferon-α are both safe and effec- tive in treating HBeAg-positive chronic hepatitis B. However,the high-dose for suppressing HBV DNA replication is faster than the standard-dose.